An RSV prefusion f vaccine that overcomes immunosenescence

Ended Project Grant Awarded Last action

Award ID
R44AG064107
Recipient
Awarding agency
Obligated
$6,175,781

Award facts

Assistance listing
93.866 Aging Research
Completion date
Originally
Funding
  • $5,186,755.00 Federal
  • $989,026.00 Non-federal
Place of performance
Brooklyn, NY 11220, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $0 $0
Amendment $984,686 $0
Amendment $984,686 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $989,026 $0
Amendment An RSV prefusion f vaccine that overcomes immunosenescence - respiratory syncytial virus (RSV) infection in the elderly causes great human suffering due to… $989,026 $989,026
Amendment $0 $0
Amendment $939,591 $0
Amendment $0 $0
Original award $299,740 $0
Show all 13

Quick answers

Who received award R44AG064107?

R44AG064107 was awarded to Calder Biosciences Inc. by National Institute on Aging (National Institutes of Health) on May 15, 2019.

How much is award R44AG064107 worth?

$6,175,781 has been obligated on R44AG064107: $5,186,755 in federal funding and $989,026 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award